Search Result

Results for "

ADCC

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Apoptosis (3) CCR (1) CD20 (1) CD38 (1) EGFR (3) Ephrin Receptor (1) Influenza Virus (1) Interleukin Related (2) Mesothelin (1) Mucin (1) PD-1/PD-L1 (1) TNF Receptor (3) Tyrosinase (1)
By Research Areas:	Cancer (24) Infection (1) Inflammation/Immunology (4)

Inhibitors & Agonists

Inhibitory Antibodies

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-P99296

Intetumumab CNTO 95; Anti-Human CD51 Recombinant Antibody	EGFR	Cancer
Intetumumab (CNTO 95) is a potent anti-EGFR monoclonal antibody that is glycoengineered for enhanced antibody-dependent cellular cytotoxicity (ADCC). Intetumumab can be used in research of cancer .

HY-P99634

Gatipotuzumab PankoMab	Mucin	Cancer
Gatipotuzumab (PankoMab) is a humanized monoclonal antibody which recognizes the tumor-specific epitope of mucin-1 (TA-MUC1). Gatipotuzumab reveals a potent tumor-specific antibody-dependent cell cytotoxicity (ADCC) .

HY-P99015

Dacetuzumab	TNF Receptor	Cancer
Dacetuzumab (SGN-40) is a humanized IgG1, anti-CD40 monoclonal antibody with anti-lymphoma activity. Dacetuzumab kills tumor cells via immune effector functions (antibody-dependent cellular cytotoxicity and phagocytosis [ADCC/ADCP]). Dacetuzumab ((SGN-40) can be used for multiple myeloma research .

HY-P9968

Nimotuzumab	EGFR	Cancer
Nimotuzumab is a humanized IgG1 monoclonal antibody targeting EGFR with a K_D of 0.21 nM. Nimotuzumab is directed against the extracellular domain of the EGFR blocking the binding to its ligands. Nimotuzumab, a strong antitumor agent, is cytolytic on target tumors by its capacity to cause antibody dependent cell mediated cytotoxicity (ADCC) and complement dependent cytotoxicity (CDC) .

HY-P99253

Mogamulizumab KW-0761	CCR	Inflammation/Immunology Cancer
Mogamulizumab (KW-0761) is a recombinant anti-CCR4 monoclonal antibody (MAb). Mogamulizumab can eliminate tumor cells by antibody-dependent cellular cytotoxicity (ADCC). Mogamulizumab can be used in the research of cancers, adult T-cell leukemia/lymphoma (ATLL), cutaneous T-cell lymphoma (CTCL) .

HY-P99167

Lucatumumab HCD122	TNF Receptor	Cancer
Lucatumumab (HCD122) is a fully human anti-CD40 antagonist monoclonal antibody, which blocks CD40/CD40L-mediated signaling. Lucatumumab efficiently mediates antibody-dependent cell-mediated cytotoxicity (ADCC) and clearance of tumor cells, can be used for refractory lymphomas, CLL and multiple myeloma research .

HY-P99437

Anbenitamab KN-026	EGFR	Cancer
Anbenitamab (KN-026) is a bispecific antibody simultaneously targeting the extracellular domains II and IV of the human HER2. Anbenitamab blocks both ligand-dependent and ligand-independent HER2 signaling pathway. The IgG1 Fc fragment of Anbenitamab binds FcRγIIIa mediates potent antibody dependent cell-mediated cytotoxicity (ADCC) and inhibits tumor cell proliferation. Anbenitamab has the potential for HER2-positive metastatic breast cancer (MBC) research .

HY-P99361

Enavatuzumab PDL192; ABT-361; Anti-TNFRSF12A/TWEAKR/CD266 Reference Antibody (enavatuzumab)	TNF Receptor	Cancer
Enavatuzumab (PDL192; ABT-361) is a humanized IgG1 monoclonal antibody targeting the receptor of TNF-like weak inducer of apoptosis (TWEAK). TWEAK (Fn14; TNFRSF12A), the natural ligand of the TWEAK receptor (TweakR), stimulates multiple cellular responses. Enavatuzumab induces tumor growth inhibition through direct TweakR signaling and antibody dependent cell-mediated cytotoxicity (ADCC). Enavatuzumab can actively recruits and activates myeloid effectors to kill tumor cells. Enavatuzumab inhibits the growth of various human TweakR-positive cancer cell lines and xenografts in vitro and in vivo .

HY-P99395

Talacotuzumab JNJ 56022473; CSL 362	Interleukin Related	Cancer
Talacotuzumab (JNJ 56022473; CSL 362) is an IgG1-type fully humanized, CD123-neutralizing monoclonal antibody containing a modified Fc structure. Talacotuzumab has K_Ds of 0.43 nM, 188 nM, 46 nM, 16.8 nM for CD123, CD32b/c, CD16-158F, CD16-158V, respectively. Talacotuzumab inhibits IL-3 binding to CD123, antagonizing IL-3 signaling in target cells. Talacotuzumab has mutated the Fc region to increase affinity for CD16 (FcγRIIIa), thereby enhancing antibody-dependent cell-mediated cytotoxicity (ADCC). Talacotuzumab is highly effective in vivo reducing leukemic cell growth in acute myeloid leukemia (AML) xenograft mouse models .

HY-P99308

Ocaratuzumab AME 133v; LY 2469298; Humanized Anti-MS4A1 Recombinant Antibody	CD20	Cancer
Ocaratuzumab (AME 133v) is an Fc-engineered humanized IgG1 anti-CD20 monoclonal antibody, with a K_d of ~100 pM. Ocaratuzumab exhibits more effective antibody-dependent cell-mediated cytotoxicity (ADCC) .

HY-P99655

Ifabotuzumab KB004	Ephrin Receptor Apoptosis	Cancer
Ifabotuzumab (KB004) is an IgG1κ antibody targeting EphA3 (K_D=610 pM). Ifabotuzumab induces tumor cell apoptosis, activates Antibody-dependent cell mediated cytotoxicity (ADCC), and damages tumor vasculature. Ifabotuzumab reduces human idiopathic pulmonary fibrosis (IPF) CCR10 ⁺ cells and improves pulmonary fibrosis .

HY-P9976A

Isatuximab (anti-CD38) 1 Publications Verification	CD38	Cancer
Isatuximab (anti-CD38) is a monoclonal antibody targeting the transmembrane receptor and extracellular enzyme CD38.Isatuximab induces tumor cell killing via fragment crystallizable (Fc)-dependent or Fc-independent mechanisms, including antibody-dependent cellular cytotoxicity (ADCC), antibody-dependent cellular phagocytosis (ADCP), and complement-dependent cytotoxicity (CDC) .

HY-P99622

Flanvotumab IMC-20D7S	Tyrosinase	Cancer
Flanvotumab (IMC-20D7S) is a human monoclonal antibody targeting to tyrosinase-related protein (TYRP1), specifically expressed in melanocytes and melanoma cells. Flanvotumab acts function via natural killing-mediated antibody-dependent cell-mediated cytotoxicity (ADCC). Flanvotumab has potent anti-tumor activity and good tolerance .

HY-P99006

Amatuximab MORab-009	Mesothelin	Cancer
Amatuximab (MORab-009) is a chimeric, humanized IgG1/k MAb that targets the cell surface mesothelin (MSLN). Mesothelin is a glycosylphosphatidyl inositol (GPI)-anchored membrane glycoprotein, which is present in a restricted set of normal adult tissues such as the mesothelium .

HY-P99833

Cosibelimab CK-301; TG-1501	PD-1/PD-L1	Cancer
Cosibelimab (CK-301; TG-1501) is a high-affinity, fully human PD-L1-blocking monoclonal antibody that binds PD-L1 and blocks its interaction with PD-1. Cosibelimab has a functional Fc domain and is capable of inducing ADCC and complement-dependent cytotoxicity (CDC)-mediated killing of PD-L1 ⁺ cell lines, including lymphoma cells .

HY-P9948

Alemtuzumab Campath-IH	Apoptosis	Cancer
Alemtuzumab (Campath-IH) is a humanized monoclonal antibody against CD52. Alemtuzumab does not cross-react with murine CD52. Alemtuzumab selectively targets the CD52 antigen to induce profound lymphocyte depletion, followed by recovery of T and B cells with regulatory phenotypes. Alemtuzumab is capable of complement-dependent cytotoxicity and antibody-dependent cell-mediated cytotoxicity (ADCC), as well as induction of apoptosis. Alemtuzumab has the potential for B-cell chronic lymphocytic leukaemia research .

HY-P99699

Lesofavumab

MHAB5553A; RG70026
Influenza Virus Infection

Lesofavumab (MHAB5553A) is a human IgG1κ anti-influenza B virus antibody .

Lesofavumab MHAB5553A; RG70026	Influenza Virus	Infection
Lesofavumab (MHAB5553A) is a human IgG1κ anti-influenza B virus antibody .

HY-P99661

Inbakicept	Interleukin Related	Cancer
Inbakicept, also known as N-803 (Nogapendekin alfa inbakicept), contains the IL-15 cytokine antibody Nogapendekin alfa (HY-P99759). Inbakicept is a dimeric human IL-15 receptor alpha (IL-15 Ra) sushi domain/human IgG1 Fc fusion protein and is an IL-15 superagonist complex. Inbakicept amplifies anti-CD20 mAb-mediated NK cell responses and antibody-dependent cellular cytotoxicity (ADCC). Inbakicept also increases degranulation and IFNγ production in cells .

HY-P99371

Lirentelimab AK002; Anti-Siglec-8 Reference Antibody (lirentelimab)	Apoptosis	Inflammation/Immunology
Lirentelimab (AK002) is a humanized IgG1 monoclonal antibody that targets sialic acid-binding Ig-like lectin 8 (SIGLEC8). Lirentelimab induces cell apoptosis of IL-5-activated eosinophils and inhibits IgE-mediated mast cell activation. Lirentelimab can be used for the research of eosinophilic gastritis and duodenitis .

Cat. No.	Product Name	Target	Research Area

HY-P99296

Intetumumab CNTO 95; Anti-Human CD51 Recombinant Antibody	EGFR	Cancer
Intetumumab (CNTO 95) is a potent anti-EGFR monoclonal antibody that is glycoengineered for enhanced antibody-dependent cellular cytotoxicity (ADCC). Intetumumab can be used in research of cancer .

HY-P99634

Gatipotuzumab PankoMab	Mucin	Cancer
Gatipotuzumab (PankoMab) is a humanized monoclonal antibody which recognizes the tumor-specific epitope of mucin-1 (TA-MUC1). Gatipotuzumab reveals a potent tumor-specific antibody-dependent cell cytotoxicity (ADCC) .

HY-P99015

Dacetuzumab	TNF Receptor	Cancer
Dacetuzumab (SGN-40) is a humanized IgG1, anti-CD40 monoclonal antibody with anti-lymphoma activity. Dacetuzumab kills tumor cells via immune effector functions (antibody-dependent cellular cytotoxicity and phagocytosis [ADCC/ADCP]). Dacetuzumab ((SGN-40) can be used for multiple myeloma research .

HY-P9968

Nimotuzumab	EGFR	Cancer
Nimotuzumab is a humanized IgG1 monoclonal antibody targeting EGFR with a K_D of 0.21 nM. Nimotuzumab is directed against the extracellular domain of the EGFR blocking the binding to its ligands. Nimotuzumab, a strong antitumor agent, is cytolytic on target tumors by its capacity to cause antibody dependent cell mediated cytotoxicity (ADCC) and complement dependent cytotoxicity (CDC) .

HY-P99253

Mogamulizumab KW-0761	CCR	Inflammation/Immunology Cancer
Mogamulizumab (KW-0761) is a recombinant anti-CCR4 monoclonal antibody (MAb). Mogamulizumab can eliminate tumor cells by antibody-dependent cellular cytotoxicity (ADCC). Mogamulizumab can be used in the research of cancers, adult T-cell leukemia/lymphoma (ATLL), cutaneous T-cell lymphoma (CTCL) .

HY-P99167

Lucatumumab HCD122	TNF Receptor	Cancer
Lucatumumab (HCD122) is a fully human anti-CD40 antagonist monoclonal antibody, which blocks CD40/CD40L-mediated signaling. Lucatumumab efficiently mediates antibody-dependent cell-mediated cytotoxicity (ADCC) and clearance of tumor cells, can be used for refractory lymphomas, CLL and multiple myeloma research .

HY-P99437

Anbenitamab KN-026	EGFR	Cancer
Anbenitamab (KN-026) is a bispecific antibody simultaneously targeting the extracellular domains II and IV of the human HER2. Anbenitamab blocks both ligand-dependent and ligand-independent HER2 signaling pathway. The IgG1 Fc fragment of Anbenitamab binds FcRγIIIa mediates potent antibody dependent cell-mediated cytotoxicity (ADCC) and inhibits tumor cell proliferation. Anbenitamab has the potential for HER2-positive metastatic breast cancer (MBC) research .

HY-P990076

Lorukafusp alfa 14.18 mAb; hu14.18-IL2; EMD 273063	Inhibitory Antibodies	Cancer
Lorukafusp alfa (14.18 mAb; hu14.18-IL2) is an immunocytokine consisting of the humanized 14.18 anti-GD2 mAb linked to IL210. Lorukafusp alfa has activity mediated by activation of antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity via the binding of hu14.18-IL2 to GD2 on the tumor cell surface, followed by binding to Fc receptors on effector cells along with activation of NK and T cells via IL2 receptor binding. Lorukafusp alfa has anti-tumor activity .

HY-P99361

Enavatuzumab PDL192; ABT-361; Anti-TNFRSF12A/TWEAKR/CD266 Reference Antibody (enavatuzumab)	TNF Receptor	Cancer
Enavatuzumab (PDL192; ABT-361) is a humanized IgG1 monoclonal antibody targeting the receptor of TNF-like weak inducer of apoptosis (TWEAK). TWEAK (Fn14; TNFRSF12A), the natural ligand of the TWEAK receptor (TweakR), stimulates multiple cellular responses. Enavatuzumab induces tumor growth inhibition through direct TweakR signaling and antibody dependent cell-mediated cytotoxicity (ADCC). Enavatuzumab can actively recruits and activates myeloid effectors to kill tumor cells. Enavatuzumab inhibits the growth of various human TweakR-positive cancer cell lines and xenografts in vitro and in vivo .

HY-P99431

KY-1044 Alomfilimab; SAR 445256	Inhibitory Antibodies	Inflammation/Immunology Cancer
KY-1044 (Alomfilimab; SAR 445256) is a fully human IgG1 antibody targeting inducible costimulatory receptor (ICOS). KY-1044 depletes ICOS ^high cells via antibody-dependent cellular cytotoxicity (ADCC) through the engagement of FcgRIIIa. KY-1044 act as a costimulatory molecule on cells expressing lower ICOS levels, such as CD8 ⁺ T_Eff cells (through FcgR-dependent clustering). KY-1044 exploit the differential expression of ICOS on T-cell subtypes to improve the intratumoral immune contexture and restore an antitumor immune response .

HY-P99395

Talacotuzumab JNJ 56022473; CSL 362	Interleukin Related	Cancer
Talacotuzumab (JNJ 56022473; CSL 362) is an IgG1-type fully humanized, CD123-neutralizing monoclonal antibody containing a modified Fc structure. Talacotuzumab has K_Ds of 0.43 nM, 188 nM, 46 nM, 16.8 nM for CD123, CD32b/c, CD16-158F, CD16-158V, respectively. Talacotuzumab inhibits IL-3 binding to CD123, antagonizing IL-3 signaling in target cells. Talacotuzumab has mutated the Fc region to increase affinity for CD16 (FcγRIIIa), thereby enhancing antibody-dependent cell-mediated cytotoxicity (ADCC). Talacotuzumab is highly effective in vivo reducing leukemic cell growth in acute myeloid leukemia (AML) xenograft mouse models .

HY-P99308

Ocaratuzumab AME 133v; LY 2469298; Humanized Anti-MS4A1 Recombinant Antibody	CD20	Cancer
Ocaratuzumab (AME 133v) is an Fc-engineered humanized IgG1 anti-CD20 monoclonal antibody, with a K_d of ~100 pM. Ocaratuzumab exhibits more effective antibody-dependent cell-mediated cytotoxicity (ADCC) .

HY-P99013

Codrituzumab GC33; RO5137382	Inhibitory Antibodies	Cancer
Codrituzumab is a monoclonal antibody targeting GPC3 (glypican-3). GPC3 is an oncofetal protein expressed on the cell surface of hepatocellular carcinoma (HCC). Codrituzumab induces antibody-dependent cellular cytotoxicity (ADCC) and inhibits tumor growth .

HY-P99653

Ianalumab VAY-736	Inhibitory Antibodies	Cancer
Ianalumab (VAY-736) is a human, decarboxylated antibody against BAFF-R. Ianalumab can block the interaction between BAFF and BAFF-R and antagonize the apoptosis protection mediated by BAFF. Ianalumab exerts antibody-dependent cytotoxic (ADCC), depending on effector cell activation mediated by immune receptor tyrosine activation motif (ITAM) .

HY-P99381

XmAb 5592	Inhibitory Antibodies	Cancer
XmAb 5592 is a humanized, Fc-engineered anti-HM1.24 antibody with enhanced binding to FcγRIIIa and FcγRIIa receptors, augments HM1.24-specific multiple myeloma (MM) cells lysis in vitro via antibody-dependent cellular cytotoxicity (ADCC) and antibody dependent cellular phagocytosis (ADCP) .

HY-P99655

Ifabotuzumab KB004	Ephrin Receptor Apoptosis	Cancer
Ifabotuzumab (KB004) is an IgG1κ antibody targeting EphA3 (K_D=610 pM). Ifabotuzumab induces tumor cell apoptosis, activates Antibody-dependent cell mediated cytotoxicity (ADCC), and damages tumor vasculature. Ifabotuzumab reduces human idiopathic pulmonary fibrosis (IPF) CCR10 ⁺ cells and improves pulmonary fibrosis .

HY-P9976A

Isatuximab (anti-CD38) 1 Publications Verification	CD38	Cancer
Isatuximab (anti-CD38) is a monoclonal antibody targeting the transmembrane receptor and extracellular enzyme CD38.Isatuximab induces tumor cell killing via fragment crystallizable (Fc)-dependent or Fc-independent mechanisms, including antibody-dependent cellular cytotoxicity (ADCC), antibody-dependent cellular phagocytosis (ADCP), and complement-dependent cytotoxicity (CDC) .

HY-P99622

Flanvotumab IMC-20D7S	Tyrosinase	Cancer
Flanvotumab (IMC-20D7S) is a human monoclonal antibody targeting to tyrosinase-related protein (TYRP1), specifically expressed in melanocytes and melanoma cells. Flanvotumab acts function via natural killing-mediated antibody-dependent cell-mediated cytotoxicity (ADCC). Flanvotumab has potent anti-tumor activity and good tolerance .

HY-P99006

Amatuximab MORab-009	Mesothelin	Cancer
Amatuximab (MORab-009) is a chimeric, humanized IgG1/k MAb that targets the cell surface mesothelin (MSLN). Mesothelin is a glycosylphosphatidyl inositol (GPI)-anchored membrane glycoprotein, which is present in a restricted set of normal adult tissues such as the mesothelium .

HY-P99591

Sontuzumab AS1402; huHMFG-1	Inhibitory Antibodies	Cancer
Sontuzumab (AS1402) is a humanizedised IgG1κ MUC1 specific monoclonal antibody. Sontuzumab binds the extracellular MUC1 peptide sequence PDTR with a K_d of ~1 nM. Sontuzumab can be used for the research of breast cancer .

HY-P99746

Murlentamab 3C23K; GM102	Inhibitory Antibodies	Inflammation/Immunology Cancer
Murlentamab (3C23K; GM102) is a humanized anti-AMHRII antibody. AMHRII is the anti-Müllerian hormone receptor. Murlentama significantly promotes macrophage-mediated antibody-dependent cell-mediated cytotoxicity (ADCC). Murlentama stimulates pro-inflammatory and anti-tumor internal environment, recruits and activates T cells. Murlentama suppresses tumors growth by inducing naïve macrophage orientation and promoting tumor-associated macrophage (TAM) reprogramming .

HY-P99833

Cosibelimab CK-301; TG-1501	PD-1/PD-L1	Cancer
Cosibelimab (CK-301; TG-1501) is a high-affinity, fully human PD-L1-blocking monoclonal antibody that binds PD-L1 and blocks its interaction with PD-1. Cosibelimab has a functional Fc domain and is capable of inducing ADCC and complement-dependent cytotoxicity (CDC)-mediated killing of PD-L1 ⁺ cell lines, including lymphoma cells .

HY-P9948

Alemtuzumab Campath-IH	Apoptosis	Cancer
Alemtuzumab (Campath-IH) is a humanized monoclonal antibody against CD52. Alemtuzumab does not cross-react with murine CD52. Alemtuzumab selectively targets the CD52 antigen to induce profound lymphocyte depletion, followed by recovery of T and B cells with regulatory phenotypes. Alemtuzumab is capable of complement-dependent cytotoxicity and antibody-dependent cell-mediated cytotoxicity (ADCC), as well as induction of apoptosis. Alemtuzumab has the potential for B-cell chronic lymphocytic leukaemia research .

HY-P99699

Lesofavumab

MHAB5553A; RG70026
Influenza Virus Infection

Lesofavumab (MHAB5553A) is a human IgG1κ anti-influenza B virus antibody .

Lesofavumab MHAB5553A; RG70026	Influenza Virus	Infection
Lesofavumab (MHAB5553A) is a human IgG1κ anti-influenza B virus antibody .

HY-P99661

Inbakicept	Interleukin Related	Cancer
Inbakicept, also known as N-803 (Nogapendekin alfa inbakicept), contains the IL-15 cytokine antibody Nogapendekin alfa (HY-P99759). Inbakicept is a dimeric human IL-15 receptor alpha (IL-15 Ra) sushi domain/human IgG1 Fc fusion protein and is an IL-15 superagonist complex. Inbakicept amplifies anti-CD20 mAb-mediated NK cell responses and antibody-dependent cellular cytotoxicity (ADCC). Inbakicept also increases degranulation and IFNγ production in cells .

HY-P99371

Lirentelimab AK002; Anti-Siglec-8 Reference Antibody (lirentelimab)	Apoptosis	Inflammation/Immunology
Lirentelimab (AK002) is a humanized IgG1 monoclonal antibody that targets sialic acid-binding Ig-like lectin 8 (SIGLEC8). Lirentelimab induces cell apoptosis of IL-5-activated eosinophils and inhibits IgE-mediated mast cell activation. Lirentelimab can be used for the research of eosinophilic gastritis and duodenitis .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: